# A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

> **NCT07845500** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 660 (estimated)

## Conditions studied

- Obesity
- Overweight and/or Obesity
- Overweight
- Treatment Of Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Tirzepatide
- **DRUG:** Berobenatide

## Key facts

- **NCT ID:** NCT07845500
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2028-02-16
- **Final completion:** 2028-02-16
- **Target enrollment:** 660 (ESTIMATED)
- **Last updated:** 2026-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07845500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07845500, "A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07845500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
